Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Ocular Therapeutix (OCUL) Misses Q2 EPS by 33c, Revenues Beat
August 7, 2020 7:19 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.64), $0.33 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.57 million versus the consensus estimate of $1.5 million.
Despite the challenges caused by the global pandemic, it has been a very productive quarter for Ocular Therapeutix, said Antony Mattessich, President and CEO. Our clinical... More
